Index Ventures Invests in Acutus Medical
New medical technology company focused on developing a breakthrough device for real time mapping of Atrial Fibrillation
8th August 2011, San Diego, USA: – Index Ventures, together with private investors, has invested an initial funding of $1 million in Acutus Medical, a newly founded medical technology company based in San Diego. The Company is developing an electrophysiological mapping technology to optimise the treatment of cardiac arrhythmias and will use the initial funding to develop prototypes of its novel device.
Acutus Medical was founded in 2011. The company’s technology allows improved mapping of the cardiac space which enables instantaneous and precise visualization of areas to be ablated in patients with cardiac arrhythmias such as atrial fibrillation and ventricular tachycardia. The technology is being co-developed in the US and Europe. Currently only around 3-5% of patients affected are treated due to a lack of adequate technologies and training.
Commenting on the investment, Kevin Johnson, London based partner at Index Ventures and Board member at Acutus Medical said, “We are delighted to invest in Acutus Medical, our fourth medical technology company. This investment underlines our commitment to the medical device space, an area with growth potential”.
About Acutus Medical:
Acutus Medical is a medical technology company committed to developing an innovative breakthrough platform technology of safe, cost effective and clinically advanced tools for the minimally invasive diagnosis (mapping) of complex cardiac arrhythmias (such as atrial fibrillation and ventricular tachycardia). The Company’s technology is being co-developed in the US and Europe and is expected to achieve CE marking within the next 18 months. Acutus Medical is located in San Diego, California and is privately funded with lead investors, Index Ventures.
About Index Ventures:
Index Ventures is a leading global venture capital firm active in technology venture investing since 1996. The firm is dedicated to helping top entrepreneurial teams in the Information Technology, Clean Technology and Life Science sectors build their companies into market defining global leaders. The firm has offices in Geneva, London and Jersey and focuses on investments from seed through growth www companies. In the life sciences field, Index.
Ventures invests in companies with disruptive platform technologies capable of growing into global leaders. It has also pioneered the asset-centric investment model, focused on investing in single assets with the potential to be first or best in class. More recently it has expanded its focus into the diagnostic/medical device areas. Current portfolio companies include Aegerion, Cellzome, Cyrenaic, Funxional Therapeutics, Micromet, Molecular Partners, Mind-NRG, NormOxys, Novocure and Sequenta. Exits of note include Addex Pharma (ADXN), Genmab (GEN), PanGenetics (Abbott) and ParAllele Bioscience (Affymetrix). For more information, please visit www.Indexventures.com.
For more information contact:
College Hill Life Sciences
Nicole Yost / Jayne Crook
Ph: +44 (0)20 7866 2020
Randy Werneth, CEO
Index Ventures (London)
Ph: +44 (0)207 154 2009 / +44 7917 207 297